CHELSEA PAYNE: Open Payments
NPI 1245852144 · LODI, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$460 in 25 payments from 10 companies in 2025. Trend: 2023 $368 · 2024 $725 · 2025 $460
Food & beverage: $460
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 7 | $131 |
| Novartis Pharmaceuticals Corporation | 3 | $60 |
| GlaxoSmithKline, LLC. | 3 | $56 |
| Novo Nordisk Inc | 3 | $53 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $47 |
| ABBVIE INC. | 2 | $34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Exact Sciences Corporation | 1 | $19 |
| Globus Medical, Inc. | 1 | $19 |
Products named: MOUNJARO, LEQVIO, AREXVY, Kerendia, Ozempic, VRAYLAR, JARDIANCE, GEMTESA.
Industry payments across CA — which companies pay providers there.
